Drug intelligence / Profile preview

mosaic HIV-1 envelope trimer immunogens

Development stage
Discontinued
Lead developer
International AIDS Vaccine Initiative
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Mosaic HIV-1 envelope trimer immunogens are a series of engineered recombinant proteins designed to address the high genetic diversity of HIV-1. These immunogens utilize "mosaic" sequences—computationally optimized sequences designed to maximize the representation of potential T-cell and B-cell epitopes from diverse global HIV-1 strains. They are typically presented in the **SOSIP** format, which stabilizes the envelope (Env) protein in its native-like, prefusion trimeric conformation through a disulfide bond (SOS) and a proline mutation (IP). By mimicking the structure of the functional HIV-1 spike, these trimers aim to elicit broadly neutralizing antibodies (bNAbs) against conserved sites of vulnerability, such as the CD4 binding site, the V3-glycan patch, and the apex. These immunogens are often administered as a cocktail (e.g., MT1, MT2, and MT3) to broaden the immune response across multiple HIV-1 clades.

Other names
Mosaic Env trimersMosaic HIV-1 envelope trimersMosaic SOSIP trimer immunogens
02

Targets

Env (HIV-1 envelope glycoprotein)CD4 (T lymphocyte surface antigen)BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on mosaic HIV-1 envelope trimer immunogens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mosaic HIV-1 envelope trimer immunogens.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call